Last reviewed · How we verify
NCT05784220: CDPP
The Canadian Diabetes Prevention Program
NA trial testing DPP Curriculum for Lifestyle Intervention in Diabetes type2 in 2,174 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | LMC Diabetes & Endocrinology Ltd. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 2,174 |
| Start date | 21 June 2019 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 September 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- DPP Curriculum for Lifestyle Intervention
Conditions studied
- Diabetes type2 — all drugs for Diabetes type2 →
Sponsor
LMC Diabetes & Endocrinology Ltd. — full company profile →
Who can join
18 and older, any sex, with Diabetes type2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
According to Diabetes Canada ("DC"), in 2015, the estimated prevalence of prediabetes in Canada (\>20 years of age) is 5.7 million people (22.1%). This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently Type 2 Diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada . There is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage. The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05784220
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes type2
Currently open trials in the same condition.
- NCT04916132 — Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors · recruiting
- NCT04880005 — Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid · NA · recruiting
- NCT04607096 — Intermittent Fasting to Improve Insulin Secretion · NA · recruiting
- NCT04101669 — RESET System Pivotal Trial (Rev F) · NA · recruiting
Other LMC Diabetes & Endocrinology Ltd. trials
Trials by the same sponsor.
- NCT06962735 — Real-world Effect of Switching From Intermittently-scanned to Real-time Continuous Glucose Monitoring (Switch CGM Retro) · completed
- NCT06236672 — Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease · completed
- NCT05029583 — Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D) · NA · unknown
- NCT04562714 — Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy · NA · completed
- NCT04327622 — Prevalence and Risk Evaluation of Diabetic Complications of the Foot in A Large Canadian Population · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05784220 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LMC Diabetes & Endocrinology Ltd.
- Last refreshed: 24 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05784220.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing